Vancouver, British Columbia-Predicting off-treatment time forintermittent androgen suppression is complex and involves manyfactors, said Laurence Klotz, MD, chief, division of urology,Sunnybrook and Women's College Health Sciences Center in Toronto.
Enzalutamide shown to improve overall survival in hormone-sensitive prostate cancer
Patients received standard-of-care testosterone suppression with either oral enzalutamide or standard non-steroidal antiandrogen therapy.
Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer
Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.
AI model able to generate high-quality synthetic prostate cancer MRIs
"The improvement in technologies could potentially assist radiation oncologists in making timely decisions,” said Himanshu Arora, PhD.
Speaking of Urology: ASCO GU 2023 Highlights
Laura Bukavina, MD, and Kyle Rose, MD, discuss some of the notable abstracts from the 2023 ASCO GU conference.
Study evaluates patient experiences with biopsy-based genomic testing during active surveillance
Michael S. Leapman, MD, MHS, highlights a study of patient experiences with tissue-based genomic testing during active surveillance for prostate cancer.
How the ongoing shortage of 177Lu-PSMA-617 in the US affects care for patients with prostate cancer
"Some of these patients newly referred don't have any other proven therapies remaining...This is the only one on the shelf that has a proven benefit. Unfortunately, we can't offer them that at this stage," says Praful Ravi, MD, BChir, MRCP.
2 Clarke Drive Cranbury, NJ 08512